Cytarabine

"Cytarabine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)

Descriptor ID	D003561
MeSH Number(s)	D03.383.742.680.245.453 D13.570.065.300 D13.570.685.245.453
Concept/Terms	Cytarabine Cytarabine Arabinofuranosylcytosine Aracytidine Cytosine Arabinoside Arabinoside, Cytosine Arabinosylcytosine Aracytine Aracytine beta-Ara C beta-Ara C Cytonal Cytonal Cytosar Cytosar Cytosar-U Cytosar U CytosarU Ara-C Ara-C Cytarabine Hydrochloride Cytarabine Hydrochloride Hydrochloride, Cytarabine

Below are MeSH descriptors whose meaning is more general than "Cytarabine".

Chemicals and Drugs [D]
Heterocyclic Compounds [D03]
Heterocyclic Compounds, 1-Ring [D03.383]
Pyrimidines [D03.383.742]
Pyrimidine Nucleosides [D03.383.742.680]
Cytidine [D03.383.742.680.245]
Cytarabine [D03.383.742.680.245.453]
Nucleic Acids, Nucleotides, and Nucleosides [D13]
Nucleosides [D13.570]
Arabinonucleosides [D13.570.065]
Cytarabine [D13.570.065.300]
Pyrimidine Nucleosides [D13.570.685]
Cytidine [D13.570.685.245]
Cytarabine [D13.570.685.245.453]

Below are MeSH descriptors whose meaning is related to "Cytarabine".

Below are MeSH descriptors whose meaning is more specific than "Cytarabine".

Cytarabine
Ancitabine

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Cytarabine" by people in this website by year, and whether "Cytarabine" was a major or minor topic of these publications.

Bar chart showing 5 publications over 4 distinct years, with a maximum of 2 publications in 2008

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2008	1	1	2
2009	1	0	1
2011	0	1	1
2014	0	1	1

Below are the most recent publications written about "Cytarabine" by people in Profiles.

Lancet JE, Uy GL, Newell LF, Lin TL, Ritchie EK, Stuart RK, Strickland SA, Hogge D, Solomon SR, Bixby DL, Kolitz JE, Schiller GJ, Wieduwilt MJ, Ryan DH, Faderl S, Cortes JE. CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematol. 2021 Jul; 8(7):e481-e491.

View in: PubMed
Lin TL, Rizzieri DA, Ryan DH, Schiller GJ, Kolitz JE, Uy GL, Hogge DE, Solomon SR, Wieduwilt MJ, Ryan RJ, Faderl S, Cortes JE, Lancet JE. Older adults with newly diagnosed high-risk/secondary AML who achieved remission with CPX-351: phase 3 post hoc analyses. Blood Adv. 2021 03 23; 5(6):1719-1728.

View in: PubMed
Lancet JE, Uy GL, Cortes JE, Newell LF, Lin TL, Ritchie EK, Stuart RK, Strickland SA, Hogge D, Solomon SR, Stone RM, Bixby DL, Kolitz JE, Schiller GJ, Wieduwilt MJ, Ryan DH, Hoering A, Banerjee K, Chiarella M, Louie AC, Medeiros BC. CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia. J Clin Oncol. 2018 09 10; 36(26):2684-2692.

View in: PubMed
Goldman S, Smith L, Galardy P, Perkins SL, Frazer JK, Sanger W, Anderson JR, Gross TG, Weinstein H, Harrison L, Shiramizu B, Barth M, Cairo MS. Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: a Children's Oncology Group Report. Br J Haematol. 2014 Nov; 167(3):394-401.

View in: PubMed
Wieduwilt MJ, Valles F, Issa S, Behler CM, Hwang J, McDermott M, Treseler P, O'Brien J, Shuman MA, Cha S, Damon LE, Rubenstein JL. Immunochemotherapy with intensive consolidation for primary CNS lymphoma: a pilot study and prognostic assessment by diffusion-weighted MRI. Clin Cancer Res. 2012 Feb 15; 18(4):1146-55.

View in: PubMed
Meeker ND, Cherry AM, Bangs CD, Frazer JK. A pediatric B lineage leukemia with coincident MYC and MLL translocations. J Pediatr Hematol Oncol. 2011 Mar; 33(2):158-60.

View in: PubMed
Lagisetty P, Vilekar P, Awasthi V. Synthesis of radiolabeled cytarabine conjugates. Bioorg Med Chem Lett. 2009 Aug 15; 19(16):4764-7.

View in: PubMed
Hartford CM, Duan S, Delaney SM, Mi S, Kistner EO, Lamba JK, Huang RS, Dolan ME. Population-specific genetic variants important in susceptibility to cytarabine arabinoside cytotoxicity. Blood. 2009 Mar 05; 113(10):2145-53.

View in: PubMed
Odenike OM, Larson RA, Gajria D, Dolan ME, Delaney SM, Karrison TG, Ratain MJ, Stock W. Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia. Invest New Drugs. 2008 Jun; 26(3):233-9.

View in: PubMed

People

Explore

Similar Concepts

Top Journals